Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea: SCALE™ - Sleep Apnoea

Conditions

• Metabolism and Nutrition Disorder
• Obesity
• Obstructive Sleep Apnoea

Eligibility Criteria

Sex

ALL

Age

18 Years - 64 Years

Healthy Volunteers

Not accepted

Interventions

• liraglutide — DRUG
  3.0 mg liraglutide administered subcutaneously (s.c., under the skin) once daily for 32 weeks + diet and exercise
• placebo — DRUG
  Placebo administered subcutaneously (s.c., under the skin) once daily for 32 weeks + diet and exercise

Study Details

This trial is conducted in North America. The aim of the trial is to investigate the effect of liraglutide in obese subjects with sleep apnoea.

Key Dates

Start date

Jun 7, 2012

Status verified

Sep 2017

Primary completion

Jun 1, 2013

Completion

Jun 17, 2013

Study Design

Enrollment

359 participants (actual)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: Liraglutide 3.0 mg
• Placebo Comparator: Placebo

Primary Outcome Measure

Change From Baseline in Apnoea-hypopnoea Index (AHI) [ Time Frame: Week 0, Week 32 ]

Locations (37)

Find similar trials in Glendale, CA

Related Studies

• Diabetes and Heart Disease Risk in Blacks
  Recruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Bethesda, Maryland
• Physical and Behavioral Traits of Overweight and Obese Adults
  Recruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Bethesda, Maryland
• Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System
  Recruiting · National Heart, Lung, and Blood Institute (NHLBI) · Washington D.C., District of Columbia
• New Heart Imaging Techniques to Evaluate Possible Heart Disease
  Recruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Bethesda, Maryland